Cargando…
Pharmacokinetics, Safety and Efficacy of Maraviroc in Treatment-experienced Pediatric Patients Infected With CCR5-Tropic HIV-1
BACKGROUND: Maraviroc is a CC-chemokine receptor 5 antagonist approved to treat adults infected with CC-chemokine receptor 5–tropic (R5) HIV-1. Study A4001031 was conducted to evaluate the pharmacokinetics, safety and efficacy of maraviroc in combination with optimized background therapy in treatmen...
Autores principales: | Giaquinto, Carlo, Mawela, Muthuhadini Patience, Chokephaibulkit, Kulkanya, Negra, Marinella Della, Mitha, Ismail Haroon, Fourie, Jan, Fang, Annie, van der Ryst, Elna, Valluri, Srinivas Rao, Vourvahis, Manoli, Zhang-Roper, Rebecca Yanhui, Craig, Charles, McFadyen, Lynn, Clark, Andrew, Heera, Jayvant |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Williams & Wilkins
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5916460/ https://www.ncbi.nlm.nih.gov/pubmed/29023357 http://dx.doi.org/10.1097/INF.0000000000001808 |
Ejemplares similares
-
The Effects of Boceprevir and Telaprevir on the Pharmacokinetics of Maraviroc: An Open-Label, Fixed-Sequence Study in Healthy Volunteers
por: Vourvahis, Manoli, et al.
Publicado: (2014) -
Once-daily maraviroc versus tenofovir/emtricitabine each combined with darunavir/ritonavir for initial HIV-1 treatment
por: Stellbrink, Hans-Jürgen, et al.
Publicado: (2016) -
No Clinical Impact of CYP3A5 Gene Polymorphisms on the Pharmacokinetics and/or Efficacy of Maraviroc in Healthy Volunteers and HIV‐1–Infected Subjects
por: Vourvahis, Manoli, et al.
Publicado: (2018) -
Maraviroc – A CCR5 Antagonist for the Treatment of HIV-1 Infection
por: Van Der Ryst, Elna
Publicado: (2015) -
Efficacy and safety of maraviroc vs. efavirenz in treatment-naive patients with HIV-1: 5-year findings
por: Cooper, David A., et al.
Publicado: (2014)